Category
ANTIHYPERTENSIVE DRUG /NEPRILYSIN INHIBITOR
ANTIHYPERTENSIVE DRUG /NEPRILYSIN INHIBITOR
Consistent
Purity
Global-Ready
Molecules
Advanced
Manufacturing
Scalable
Production
Partnership
Support
Sacubitril Sodium API has been developed by ASANA Pharmaceutical as part of its cardiovascular therapeutic line. Sacubitril Sodium API, listed under CAS number 149690-05-1, acts as a neprilysin inhibitor and is primarily used in combination therapies for the treatment of chronic heart failure and hypertension.
ASANA Pharmaceutical is committed to the research, development, and manufacturing of high-purity cardiovascular APIs such as Sacubitril Sodium. With core strengths in peptide chemistry and complex molecule handling, ASANA ensures consistent production of antihypertensive agents aligned with global regulatory standards. Our facilities support clients across North America, Europe, and Asia with scalable capacity and strict quality control.
ASANA Pharmaceutical collaborates with industry leaders in formulation science, clinical research, and regulatory affairs to deliver next-generation cardiovascular therapies. Sacubitril Sodium [CAS No. 149690-05-1], a neprilysin inhibitor, is a key component in heart failure management when combined with angiotensin receptor blockers. It plays a critical role in improving outcomes for patients with reduced ejection fraction. As heart health continues to be a major global focus, ASANA is dedicated to delivering:
Sacubitril Sodium API are available on public databases such as Wikipidia!